EGI.L Regulatory News (EGI)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

13 JULY 2017

Extension of Time to Return Form of Declarations

EUGENE, OREGON, USA, 13 July 2017 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, announces that further to the publication of the Proxy Statement by Electrical Geodesics Inc. on 26 June 2017 (the "Proxy Statement"), the deadline for Stockholders to return a Form of Declarations to the Company is being extended past the 12 July 2017 date originally set forth in the Proxy Statement to 18 July 2017.

Pursuant to the timetable set out in the Proxy Statement the Acquisition is expected to complete on 20 July 2017, subject to satisfaction or waiver of other conditions to closing as provided for in the Merger Agreement and as disclosed in the Proxy Statement.

To the extent that Stockholders have yet to complete and return the Form of Declarations in accordance with the instructions set out in the Proxy Statement under the heading "Action to be Taken", they are encouraged to do so as soon as possible and no later than 18 July 2017. The Form of Declarations is available on the Company's website. Receipt of the completed Form of Declarations is a condition to payment of the Acquisition Price.

Unless otherwise provided, capitalised terms used but not otherwise defined in this announcement shall have the meanings set out in the Proxy Statement.

For more information contact:

Electrical Geodesics, Inc. in Summary

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic and neuromodulation products used to monitor, interpret and modulate brain activity, based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalise on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

See our website www.egi.com